Overview

A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab

Status:
Terminated

Trial end date:
2019-12-18

Target enrollment:

Participant gender:

Summary

A study to evaluate the efficacy and tolerability of ABT-165 plus FOLFIRI compared to bevacizumab plus FOLFIRI in participants with previously treated metastatic adenocarcinoma of the colon or rectum.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Treatments:

Bevacizumab
Fluorouracil
Irinotecan
Leucovorin